ATRA

Atara BiotherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$14.00

+68.9% vs current

Most likely

Base case

50%

Probability

Target price

$7.50

-9.5% vs current

B-

Bear case

30%

Probability

Target price

$4.00

-51.7% vs current

AI sentiment snapshot

Latest data as of 2026-07-15

AI commentary

News flow is concentrated around Q1 results, regulatory path and corporate updates. Social sentiment, options skew, short interest and employee-rating data are unavailable in the packet; no analyst revision or target-change evidence is available. The deterministic prior is negative, so the setup is better treated as cautious event monitoring than as a confirmed recovery thesis.

RankAlpha Sentiment Codex - 2026-07-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-10-13eventPotential tab-cel BLA resubmission pathHigh impact

Atara said the FDA agreed that a single-arm study with an appropriate historical control could support a potential tab-cel resubmission, with a further regulatory update anticipated in Q3 2026. This is a meaningful but execution-dependent catalyst. [#PR-EARNINGS-2026-05-13]

2026-10-13catalystNear-term earnings-quality and cash-burn overhangHigh impact

Q1 2026 revenue was $0.5 million, net loss was $4.1 million, and the prior-year comparison benefited from a one-time revenue acceleration. The low recurring revenue base leaves the stock sensitive to regulatory delays and financing concerns. [#SEC-8K-2026-05-12]

2027-07-15catalystRunway extension and operating-cost resetHigh impact

Cash, cash equivalents and short-term investments were $8.4 million at March 31, 2026; Atara said $4.8 million of subsequent ATM proceeds and operating efficiencies should fund planned operations into mid-2027. Financing dependence and dilution remain important offsets. [#PR-EARNINGS-2026-05-13]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-15 • Updated nightlySource: Internal modelMethodology